常熟药明康德新药开发有限公司

Changshu operation of WuXi AppTec, the Chinese pharmaceutical, biotechnology and medical device research and manufacturing platform incorporated on 1 December 2000 and headquartered in Shanghai, with sites across Tianjin, Wuhan, Suzhou, Wuxi, Changzhou, Nanjing, Beijing, Shanghai and Guangzhou and subsidiaries in the United States, Iceland, Germany, Israel and South Korea. Delivers integrated end-to-end research, development and manufacturing under its CRDMO model, covering small molecule drug research and production, biology research, preclinical testing and clinical trial services for around 6,000 partners in more than 30 countries.